Papatheodoridis GV, Dalekos GN, Idilman R, et al. - Looking at patients in the multicenter European PAGE-B cohort, researchers examined if patients receiving tenofovir disoproxil fumarate (TDF) vs entecavir (ETV) differ in hepatocellular carcinoma (HCC) incidence or any other patient outcomes. They assessed 1,935 Caucasians with chronic hepatitis B (CHB), with or without compensated cirrhosis, who underwent treatment with either ETV (n = 772) or TDF (n = 1,163) monotherapy. Up to 12 years, similar rates of hepatocellular carcinoma, biochemical/virological response, HBsAg loss and mortality were seen among Caucasians with CHB treated with ETV vs TDF. However, relative to ETV treated patients, those receiving TDF more frequently had elastographic reversion of cirrhosis at year 5.